Anti-BCMA CAR-T cells is under clinical development by Eugia Pharma Specialties and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anti-BCMA CAR-T cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-BCMA CAR-T cells overview
Gene-modified cell therapy is under development for the treatment of relapsed and refractory multiple myeloma (RRMM). The therapeutic candidate comprises autologous T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing BCMA. It is administered through intravenous route.
Eugia Pharma Specialties overview
Eugia Pharma Specialties is a pharmaceutical company. It specialises in the development of sophisticated injectable hormonal and cancer drugs. The company is headquartered in India.
For a complete picture of Anti-BCMA CAR-T cells’s drug-specific PTSR and LoA scores, buy the report here.